For example, dual-targeting approaches that pair CSPG4-specific CAR T-cells with those targeting other ovarian cancer antigens, such as ErbB2, mesothelin, or TAG-72, could address this limitation. This evidence concerns the gene CSPG4 and ovarian carcinoma.